Brief: SciBase Holding Updates On New Clinical Studies Of Nevisense
16/09/2020 07:15
Sept 16 (Reuters) - SciBase Holding AB (publ) SCIB.ST :
* NEW CLINICAL STUDIES SHOW IMPROVED MELANOMA DETECTION BY
US
CLINICIANS WITH NEVISENSE
* NUMBER OF `MISSED MELANOMAS' FELL FROM ABOUT 7% TO < 1%
* OVERALL SENSITIVITY (ABILITY TO CORRECTLY IDENTIFY
MELANOMA)
INCREASED ON AVERAGE ACROSS GROUPS BY 14% AND SPECIFICITY
(ABILITY TO ACCURATELY IDENTIFY BENIGN MOLES) BY 10.2%
* IN TOTAL, CLINICIANS IDENTIFIED 1,343 MORE MELANOMAS WITH
NEVISENSE COMPARED TO VISUAL EVALUATION ALONE
* ALL CLINICIAN TYPES (DERMATOLOGISTS, NURSES AND RESIDENTS)
IMPROVED A SIMILAR AMOUNT, AND CLINICIANS WITH LOWEST NUMBER OF
CORRECT EVALUATIONS IMPROVED MOST
* IN JAAD STUDY, DERMATOLOGISTS IMPROVED THEIR SENSITIVITY
FROM 84
TO 98%, THEIR SPECIFICITY FROM 34% TO 44% AND THEIR NNB (NUMBER
NEEDED TO BIOPSY) FROM 6.3 TO 5.3
Source text for Eikon: ID:nWkr2SyMxw
Further company coverage: SCIB.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))